Please login to the form below

Not currently logged in
Email:
Password:

F-star appoints GSK's Neil Brewis

He joins the UK antibody firm as its chief scientific officer
F-Star

Cambridge-based antibody research company F-Star has appointed Dr Neil Brewis as chief scientific officer. 

Brewis joins from GlaxoSmithKline where he served as vice president and head head of biopharmaceutical research, leading a global team of 300 scientists who advanced numerous monoclonal antibodies, antibody fragments, and protein therapeutics from target validation into early clinical development.

He said: “F-Star is an emerging world leader in bispecfic antibody drug discovery and I am delighted to join the company at this exciting time to help maximise the potential of the technology and progress compounds clinical development.”

Brewis also has 20 years of experience in drug discovery and development prior to joining GSK.

John Haurum CEO of F-Star, said: “We are very pleased to welcome Neil to our team. His significant track record and expertise in applying antibody technologies to discover and develop clinical products will further enable us to move our portfolio of immuno-oncology compounds into the clinic.

“This appointment strengthens our experienced management team and supports F-star's strategy to lead the bispecific antibody space in immuno-oncology.

“It also demonstrates the unmatched attraction of Cambridge as the foremost biotech cluster in Europe, serving as a key hub for biopharmaceutical companies and academic excellence within antibody drug discovery and development.”

5th November 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...